Evidence mapPaperPMID 37947085Full record

ArticleCirculation2024

Development and Validation of the American Heart Association's PREVENT Equations.

Sadiya S Khan, Kunihiro Matsushita, Yingying Sang, Shoshana H Ballew, Morgan E Grams, Aditya Surapaneni, Michael J Blaha, April P Carson, Alexander R Chang, Elizabeth Ciemins and 18 more

Erratum issued Registry-linked trialAbstract read
In one paragraph

Article in Circulation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07791589 (Fibrosis Versus Metabolic Risk in MASLD), which is not on this map. Cited by 561 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
561citing papers in PubMed, 5 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07791589 completednot on this mapstarted 2026, after this paper: background citation

Fibrosis Versus Metabolic Risk in MASLD: Age-Adjusted Associations With PREVENT Cardiovascular Risk

TypeobservationalSponsorÖzgür BahadırRan2026 to 2026Enrolled271ConditionsMetabolic Dysfunction-Associated Steatotic Liver Disease
3 · Its place in the literature

Who cites it

561 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Guideline
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Long-term cardiovascular risk with cardiovascular-kidney-metabolic syndrome in U.S adults.American heart journal plus : cardiology research and practice · 2026
    Article

501 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Sadiya S KhanDepartment of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.S.K.).ORCID 0000-0003-0643-1859
Kunihiro MatsushitaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (K.M., Y.S., S.H.B., J.C.).ORCID 0000-0002-7179-718X
Yingying SangDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (K.M., Y.S., S.H.B., J.C.).ORCID 0000-0002-6179-7864
Shoshana H BallewDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (K.M., Y.S., S.H.B., J.C.).ORCID 0000-0002-7547-3764
Morgan E GramsDepartment of Medicine, Division of Precision Medicine, New York University Grossman School of Medicine, New York, NY (M.E.G., A.S.).ORCID 0000-0002-4430-6023
Aditya SurapaneniDepartment of Medicine, Division of Precision Medicine, New York University Grossman School of Medicine, New York, NY (M.E.G., A.S.).ORCID 0000-0003-4978-5980
Michael J BlahaJohns Hopkins Ciccarone Center for Prevention of Cardiovascular Disease, Baltimore, MD (M.J.B.).ORCID 0000-0001-5138-9683
April P CarsonUniversity of Mississippi Medical Center, Jackson (A.P.C.).ORCID 0000-0002-7970-6756
Alexander R ChangDepartments of Nephrology and Population Health Sciences, Geisinger Health, Danville, PA (A.R.C.).ORCID 0000-0002-8114-7447
Elizabeth CieminsAMGA (American Medical Group Association), Alexandria, VA (E.C.).ORCID 0000-0003-1262-7946
Alan S GoDivision of Research, Kaiser Permanente Northern California, Oakland; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA; Departments of Epidemiology, Biostatistics and Medicine, University of California, San Francisco; Department of Medicine (Nephrology), Stanford University School of Medicine, Palo Alto, CA (A.S,G.).ORCID 0000-0001-9109-0811
Orlando M GutierrezDepartments of Epidemiology and Medicine, University of Alabama at Birmingham (O.M.G.).ORCID 0000-0001-6593-3571
Shih-Jen HwangNational Heart, Lung, and Blood Institute, Framingham, MA (S.-J.H.).ORCID 0000-0002-2129-5704
Simerjot K JassalDivision of General Internal Medicine, University of California, San Diego and VA San Diego Healthcare, CA (S.K.J.).ORCID 0000-0001-6781-2220
Csaba P KovesdyMedicine-Nephrology, Memphis Veterans Affairs Medical Center and University of Tennessee Health Science Center, Memphis (C.P.K.).
Donald M Lloyd-JonesDepartment of Preventive Medicine, Northwestern University, Chicago, IL (D.M.L.-J.).ORCID 0000-0003-0847-6110
Michael G ShlipakDepartment of Medicine, Epidemiology, and Biostatistics, University of California, San Francisco, and San Francisco VA Medical Center (M.G.S.).ORCID 0000-0002-9559-204X
Latha P PalaniappanCenter for Asian Health Research and Education and the Department of Medicine, Stanford University School of Medicine, CA (L.P.P.).ORCID 0000-0002-1245-665X
Laurence SperlingDepartment of Cardiology, Emory University, Atlanta, GA (L.S.).ORCID 0000-0001-9417-6370
Salim S ViraniDepartment of Medicine, The Aga Khan University, Karachi, Pakistan; Texas Heart Institute and Baylor College of Medicine, Houston (S.S.V.).ORCID 0000-0001-9541-6954
Katherine TuttleProvidence Medical Research Center, Providence Inland Northwest Health, Spokane, WA; Kidney Research Institute and Institute of Translational Health Sciences, University of Washington, Seattle (K.T.).ORCID 0000-0002-2235-0103
Ian J NeelandUH Center for Cardiovascular Prevention, Translational Science Unit, Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA), Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, OH (I.J.N.).ORCID 0000-0003-2831-3618
Sheryl L ChowDepartment of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, CA (S.L.C.).
Janani RangaswamiWashington DC VA Medical Center and George Washington University School of Medicine (J.R.).ORCID 0000-0002-4313-9825
Michael J PencinaDepartment of Biostatistics, Duke University Medical Center, Durham, NC (M.J.P.).ORCID 0000-0002-1968-2641
Chiadi E NdumeleDivision of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD (C.E.N.).ORCID 0000-0002-1603-282X
Josef CoreshDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (K.M., Y.S., S.H.B., J.C.).ORCID 0000-0002-4598-0669
Chronic Kidney Disease Prognosis Consortium and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group

Funding

OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository CoreOT2HL161847 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2021 to 2025
$481.6M
AIM-AHEAD Coordinating Center - All Four CoresOT2OD032581 · OD · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · 2021 to 2025
$93.8M
Institute of Translational Health SciencesUL1TR002319 · UNIVERSITY OF WASHINGTON · 2025 to 2025
$10.2M
Central Hub for Kidney Precision MedicineU24DK114886 · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2025 to 2025
$4.2M
Tulane Clinical Center for Chronic Renal Insufficiency Cohort StudyU01DK060963 · TULANE UNIVERSITY OF LOUISIANA · 2001 to 2025
$2.7M
Tulane COBRE for Clinical and Translational Research in Cardiometabolic DiseasesP20GM109036 · TULANE UNIVERSITY OF LOUISIANA · 2025 to 2025
$2.2M
Continuation of the Chronic Renal Insufficiency Cohort (CRIC)U24DK060990 · UNIVERSITY OF PENNSYLVANIA · 2025 to 2025
$1.1M
CureGN-Penn PCCU01DK100846 · UNIVERSITY OF PENNSYLVANIA · 2025 to 2025
$1.1M
Chronic Kidney Disease Prognosis Consortium (CKD-PC)R01DK100446 · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2025 to 2025
$855k
Prediction of Chronic Kidney Disease by Simulation Modeling to Improve the Health of Minority PopulationsR01MD014712 · NIMHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ALEX BUI, Susanne B Nicholas · 2022 to 2023
$749k
META - Mentor, Educate, Train, Advocate: Patient Oriented Researchers in Cardiometabolic DiseaseK24HL150476 · NHLBI · STANFORD UNIVERSITY · 2022 to 2025
$479k
NCATS NIH HHS UL1 TR002319NHLBI NIH HHS HHSN268201700002INHLBI NIH HHS K24 HL150476NHLBI NIH HHS OT2 HL161847NHLBI NIH HHS R21 HL165376NIDDK NIH HHS R01 DK100446NIDDK NIH HHS U01 DK060963NIDDK NIH HHS U01 DK100846NIDDK NIH HHS U24 DK060990NIDDK NIH HHS U2C DK114886NIDDK NIH HHS U54 DK083912NIGMS NIH HHS P20 GM109036NIH HHS OT2 OD032581NIMHD NIH HHS R01 MD014712
6 · The paper itself

Abstract

backgroundMultivariable equations are recommended by primary prevention guidelines to assess absolute risk of cardiovascular disease (CVD). However, current equations have several limitations. Therefore, we developed and validated the American Heart Association Predicting Risk of CVD EVENTs (PREVENT) equations among US adults 30 to 79 years of age without known CVD.

methodsThe derivation sample included individual-level participant data from 25 data sets (N=3 281 919) between 1992 and 2017. The primary outcome was CVD (atherosclerotic CVD and heart failure). Predictors included traditional risk factors (smoking status, systolic blood pressure, cholesterol, antihypertensive or statin use, and diabetes) and estimated glomerular filtration rate. Models were sex-specific, race-free, developed on the age scale, and adjusted for competing risk of non-CVD death. Analyses were conducted in each data set and meta-analyzed. Discrimination was assessed using the Harrell C-statistic. Calibration was calculated as the slope of the observed versus predicted risk by decile. Additional equations to predict each CVD subtype (atherosclerotic CVD and heart failure) and include optional predictors (urine albumin-to-creatinine ratio and hemoglobin A1c), and social deprivation index were also developed. External validation was performed in 3 330 085 participants from 21 additional data sets.

resultsAmong 6 612 004 adults included, mean±SD age was 53±12 years, and 56% were women. Over a mean±SD follow-up of 4.8±3.1 years, there were 211 515 incident total CVD events. The median C-statistics in external validation for CVD were 0.794 (interquartile interval, 0.763-0.809) in female and 0.757 (0.727-0.778) in male participants. The calibration slopes were 1.03 (interquartile interval, 0.81-1.16) and 0.94 (0.81-1.13) among female and male participants, respectively. Similar estimates for discrimination and calibration were observed for atherosclerotic CVD- and heart failure-specific models. The improvement in discrimination was small but statistically significant when urine albumin-to-creatinine ratio, hemoglobin A1c, and social deprivation index were added together to the base model to total CVD (ΔC-statistic [interquartile interval] 0.004 [0.004-0.005] and 0.005 [0.004-0.007] among female and male participants, respectively). Calibration improved significantly when the urine albumin-to-creatinine ratio was added to the base model among those with marked albuminuria (>300 mg/g; 1.05 [0.84-1.20] versus 1.39 [1.14-1.65];

conclusionsPREVENT equations accurately and precisely predicted risk for incident CVD and CVD subtypes in a large, diverse, and contemporary sample of US adults by using routinely available clinical variables.

Indexed as

AtherosclerosisCardiovascular DiseasesHeart FailureAdultAgedAlbuminsAmerican Heart AssociationCreatinineFemaleGlycated HemoglobinHumansMaleMiddle AgedRisk AssessmentRisk FactorsAlbuminsCreatinineGlycated Hemoglobincardiovascular diseasesheart failurekidney diseasesmodels, cardiovascularrisk assessmentsocial determinants of health

Identifiers

PMID37947085
PMCPMC10910659

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.